Filtered By:
Drug: Celexa

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 35 results found since Jan 2013.

TALOS: a multicenter, randomized, double‐blind, placebo‐controlled trial to test the effects of citalopram in patients with acute stroke
DiscussionSSRI treatment is well tolerated and overall beneficial in the wake of stroke; it may also be neuroprotective and prevent new vascular events.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: Kristian Lundsgaard Kraglund, Janne Kaergaard Mortensen, Erik Lerkevang Grove, Søren Paaske Johnsen, Grethe Andersen Tags: Protocol Source Type: research

Effect of acupuncture plus Tai Ji Quan on the recovery of neurological function and depression state in post-stroke depression patients
ConclusionAcupuncture plus Tai Ji Quan can produce a significant efficacy in improving the limb motor function and depression in post-stroke depression patients.
Source: Journal of Acupuncture and Tuina Science - April 1, 2018 Category: Complementary Medicine Source Type: research

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
CONCLUSION: There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients. However, compared with a placebo, both drugs improved post-stroke motor function. PMID: 29783900 [PubMed - as supplied by publisher]
Source: Clinical Rehabilitation - May 1, 2018 Category: Rehabilitation Authors: Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E Tags: Clin Rehabil Source Type: research

A Case Report of Acute Intracerebral Vascular Ischemic Stroke After Treatment with Dihydroergotamine in a * Patient with New Onset of Migraine New Daily Persistant Headache with Thunderclap Onset (S41.008)
CONCLUSIONS: We report this case of a Stroke occuring in a patient who failed conventional outpatient management of sudden onset migraine-like headache that we suspect may have been on the spectrum of RCVS. Prior to this no reports have been published on a stroke possibly being a side effect or complication of DHE therapy. One prior report has suggested DHE caused RCVS in a migraine patient on citalopram, supporting the concept that DHE should be avoided in the setting of recent onset RCVS.Disclosure: Dr. Ghafoor has nothing to disclose. Dr. Young has received personal compensation for activities with Merck & Co. Inc. ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ghafoor, S., Young, W. Tags: Headache: Clinical Source Type: research

Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation
Conclusion: There was no difference in cognition between citalopram and placebo-treated patients according to the genotype group. Our results indicate, however, that low expression SERT genotype may contribute to reduced cognitive function post stroke as placebo-treated patients with low SERT expression tended to score lower on the SDMT. The significant difference in SDMT scores between low and high expression patients was present only in the placebo-treated group, thereby warranting further exploration of the potential effect of early citalopram treatment on cognitive functioning. Our results are preliminary and need repl...
Source: Cerebrovascular Diseases - March 7, 2019 Category: Neurology Source Type: research

Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study
This study will evaluate the clinical efficacy of Danzhi Xiaoyao Powder in the treatment of PSD. The results of this study will provide reliable evidence for the clinical use of Xiaoyao Powder in the treatment of PSD. Trial registration: Open Science Framework Registration number: DOI 10.17605/OSF.IO/5V926
Source: Medicine - October 22, 2021 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Effectiveness and safety of Wuling capsule for post stroke depression: A systematic review.
CONCLUSION: Wuling capsule appeared to present certain antidepressant effect compared to no treatment control. With a combination of several Western medicines, Wuling capsule could be helpful in strengthening efficacy and reducing the incidence of adverse events as an alternative choice in the treatment of PSD. However, due to the limited number of included trials and relatively moderate methodological quality in the majority of studies, further large scale and rigorously designed trials are warranted to confirm the effectiveness and safety of Wuling capsule for post stroke depression. PMID: 24906594 [PubMed - as supplied by publisher]
Source: Complementary Therapies in Medicine - June 1, 2014 Category: Complementary Medicine Authors: Peng L, Zhang X, Kang DY, Liu XT, Hong Q Tags: Complement Ther Med Source Type: research

Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionsAdministration of SSRIs may improve gross motor function, reduce disability and enhance QOL for patients recovering from stroke.
Source: Clinical Drug Investigation - July 29, 2017 Category: Drugs & Pharmacology Source Type: research

Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis.
Conclusions: Paroxetine is probably the best option to consider for patients with PSD. To get a quicker relief of depression, duloxetine might be useful for its rapid onset of antidepressant action. The tolerability was comparable among all the antidepressants. But more high-quality RCTs are needed. PMID: 29805769 [PubMed]
Source: Oncotarget - May 31, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Clinical effects and safety of electroacupuncture for the treatment of post-stroke depression: a systematic review and meta-analysis of randomised controlled trials.
CONCLUSION: There was no significant difference between EA and antidepressants in the severity of depression, however EA caused fewer adverse events than antidepressants. Additional larger scale RCTs with rigorous study design are required. PMID: 29776950 [PubMed - as supplied by publisher]
Source: Acupuncture in Medicine - May 18, 2018 Category: Complementary Medicine Authors: Li XB, Wang J, Xu AD, Huang JM, Meng LQ, Huang RY, Xu J Tags: Acupunct Med Source Type: research

The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis
Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.Systematic Review Registration: PROSPERO, identifier [CRD42021227452].
Source: Frontiers in Neurology - October 20, 2021 Category: Neurology Source Type: research

Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects
Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al.. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91. Context By 2050, an estimated 135 million people will suffer from dementia globally.1 Caring for those with Alzheimer's disease (AD)—by far the most common form of dementia—is expensive, costing an estimated £23 billion per annum in the UK. As the disease progresses, neuropsychiatric symptoms such as depression, agitation and behavioural disturbance appear. The incidence of these symptoms, which predict institutionalisation an...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Underwood, B. R., Fox, C. Tags: Neurogastroenterology, Geriatric medicine, Dementia, Drugs: CNS (not psychiatric), Sleep disorders (neurology), Stroke, Drugs: psychiatry, Eating disorders, Memory disorders (psychiatry), Psychiatry of old age, Psychotic disorders (incl schizophrenia), Sl Source Type: research

Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis
Background and Purpose: To evaluate the citalopram in post-stroke depression treatment, we compared its use to other selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and traditional Chinese medicines (TCMs). Methods: We searched databases up to May 2015. Relative risk (RR) for dichotomous data and standard mean difference (SMD) for continuous variables were analyzed using Stata 13.1. Results: The RR of the efficacy index compared to TCAs was 1.07 (95% CI 1.01-1.14, p = 0.02), and the Hamilton Depression Scale with citalopram was lower than that found with other SSRIs (SMD -0.43, 95% CI -0.85 to -0.01, p
Source: European Neurology - November 11, 2015 Category: Neurology Source Type: research

Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis
Conclusions: The results of this study may present helpful evidence to determine whether citalopram is an effective management for patients with PSD. PROSPERO registration number: PROSPERO CRD42020171015.
Source: Medicine - June 26, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Effect of transcranial magnetic stimulation in combination with citalopram on patients with post-stroke depression
ConclusionOur study found TMS in combination with citalopram is conducive to improving depression status and neuropsychological function, which holds great promise for treating PSD.
Source: Frontiers in Human Neuroscience - October 7, 2022 Category: Neuroscience Source Type: research